Taurolidine
| Taurolidine | |
|---|---|
| File:Taurolidine.png | |
| style="background: #F8EABA; text-align: center;" colspan="2" | Identifiers | |
| CAS number | 19388-87-5 |
| PubChem | 29566 |
| SMILES | Script error: No such module "collapsible list". |
| style="background: #F8EABA; text-align: center;" colspan="2" | Properties | |
| Molecular formula | C7H16N4O4S2 |
| Molar mass | 284.36 g mol−1 |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
Taurolidine ([bis(1,1-dioxoperhydro-1,2,4-thiadiazinyl-4)-methane) is a drug with antimicrobial and anti-lipopolysaccharide properties. Derived from the amino acid taurine, its immunue modulatory action is reported to be mediated with priming and activation of macrophages and polymorphonuclear leukocytes.[1]
Taurolidine has been used to treat patients with peritonitis and as an antiendoxic agent in patients with Systemic inflammatory response syndrome.[2] Additionally, taurolidine demonstrates some anti-tumor properties, with positive results seen in early-stage clinical investigations using the drug to treat gastrointestinal malignancies and tumors of the central nervous system.[2]
Taurolidine has been investigated for the prevention of central venous catheter-related infections; while there is positive in vivo and in vitro evidence supporting such an application, the current evidence is "insufficient to warrant routine use of taurolidine".[3]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
